We designed the present study to evaluate the manageability and tolerability of a therapeutic schedule consisting of a short HD IL-2 infusion repeated every 21 days, corticosteroids to reduce the risk of capillary leak syndrome, and RT to exploit the synergistic effect. Here, IL2 is linked to capillary leak syndrome.